Emily Helmes

Vice President, Regulatory

Emily Bulian Helmes is Vice President of Regulatory at BiomEdit, where she leads global regulatory strategy and quality management to support the commercialization of BiomEdit’s Programmable Veterinary Biologics^™, engineered living therapeutics addressing infectious disease, sustainability, and chronic disease across five animal species. With more than 20 years of regulatory affairs experience, she brings a balanced perspective of technical expertise, business strategy, and executive leadership.

With senior leadership experience spanning BiomEdit, Elanco Animal Health, and ChemGen Corp., Emily has built and led high-performing cross-functional teams across regulatory affairs and quality systems, and worked collaboratively with product development and global market access. She is recognized for aligning complex regulatory strategies with broader business objectives, fostering organizational agility, and driving innovation in highly regulated environments.

At BiomEdit, Emily leads the regulatory strategy that resulted in the conditional licensure of a first-in-class veterinary biologic for poultry health, Clostridium Perfringens Alpha Toxin and NetB Antibody Fragment, Live Limosilactobacillus Vector or CPerf LLV* (aka BE-101), achieving approval on an accelerated timeline and positioning the company for commercial growth. As a trusted executive leader, she contributes to corporate strategy and industry advancement through active leadership roles with organizations including AFIA and ETA and as an industry advisor with AAFCO, helping shape policy and accelerate innovation across the animal health sector.

Emily holds a degree in chemistry from Tufts University with an MBA from the University of California, Berkeley Haas School of Business.